Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation…
3 analysts rate ADGM Buy on consensus.
Consensus price target: $3.33 (+5363.93% upside from $0.06)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Kaster Deborah Chief Financial Officer | Dec 16, 2025 | Purchase | 15,000 | $17.97K |
| Usen Todd director, Chief Executive Officer | Dec 12, 2025 | Purchase | 207,315 | $225.97K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | -100% | $-25.08M |
| 2024 | $269K | -10.33% | $-53.76M |
| 2023 | $300K | +58.73% | $-38.15M |
Stock data for ADGM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics